June 22, 2021

Olivier Taelman Chief Executive Officer Nyxoah SA Rue Edouard Belin 12 1435 Mont-Saint-Guibert, Belgium

> Re: Nyxoah SA Registration

Statement on Form F-1

Filed June 10, 2021 File No. 333-257000

Dear Dr. Taelman:

We have reviewed your registration statement and have the following comments. In

some of our comments, we may ask you to provide us with information so we may better

understand your disclosure.

Please respond to this letter by amending your registration statement and providing the

requested information. If you do not believe our comments apply to your facts and

circumstances or do not believe an amendment is appropriate, please tell us why in your

response.

After reviewing any amendment to your registration statement and the information you

provide in response to these comments, we may have additional comments.

Registration Statement on Form F-1, Filed June 10, 2021

Cover Page

1. We note that certain existing investors have indicated an interest to purchase in the offering. Please revise to provide the aggregate amount the investors have indicated they would be interested in purchasing and name any such investors that are affiliated with you or if such purchase by such investor would materially affect the beneficial ownership table (i.e., such investor would hold over 3% ownership), and if so state the percentage change. Olivier Taelman

FirstName

Nyxoah SALastNameOlivier Taelman

Comapany

June NameNyxoah SA

22, 2021

June 22,

Page 2 2021 Page 2

FirstName LastName

Intellectual Property, page 114

We note your response to prior comment 3 and your revised disclosure of the minimum

annual royalty payments you will make to Vanderbilt that are creditable against the earned

royalties. Please revise your disclosure to include the earned royalty payment that you

will make to Vanderbilt. Also please file as an exhibit any related agreements between

the company and Vanderbilt.

We remind you that the company and its management are responsible for the accuracy

and adequacy of their disclosures, notwithstanding any review, comments, action or absence of

action by the staff.

Refer to Rules 460 and 461 regarding requests for acceleration. Please

You may contact Julie Sherman at 202-551-3640 or Kevin Kuhar at 202-551-3662 if you have questions regarding comments on the financial statements and related matters. Please contact Margaret Schwartz at 202-551-7153 or Tom Kluck at 202-551-3233 with any other questions.

Sincerely,

Division of

Corporation Finance

Office of Life

Sciences

cc: John Rudy, Esq.